{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:23:31Z","timestamp":1790054611670,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1053\/j.seminoncol.2009.10.013","type":"journal-article","created":{"date-parts":[[2009,12,5]],"date-time":"2009-12-05T09:11:38Z","timestamp":1260004298000},"page":"S26-S36","source":"Crossref","is-referenced-by-count":43,"special_numbering":"S3","title":["Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma"],"prefix":"10.1053","volume":"36","author":[{"given":"Gary R.","family":"Hudes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Berkenblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Feingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Dutcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2009.10.013_bib2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1081\/CNV-200055962","article-title":"Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review","volume":"23","author":"Moore","year":"2005","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib4","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","article-title":"Renal-cell carcinoma","volume":"353","author":"Cohen","year":"2005","journal-title":"N Engl J Med"},{"issue":"suppl 10","key":"10.1053\/j.seminoncol.2009.10.013_bib6","doi-asserted-by":"crossref","first-page":"x25","DOI":"10.1093\/annonc\/mdm411","article-title":"Treatment options in renal cell carcinoma: past, present and future","volume":"18","author":"Oudard","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/14737140.8.3.481","article-title":"Improving outcomes in patients with advanced renal cell carcinoma","volume":"8","author":"Sosman","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib8","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib9","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib12","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib13","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib16","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","article-title":"The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy","volume":"13","author":"Abraham","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib17","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib19","series-title":"Torisel [package insert]","year":"2008"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib20","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMe068263","article-title":"Renal-cell carcinoma\u2014molecular pathways and therapies","volume":"356","author":"Brugarolas","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib22","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","article-title":"Role of VHL gene mutation in human cancer","volume":"22","author":"Kim","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(02)00044-2","article-title":"The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma","volume":"1","author":"Maranchie","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib25","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1158\/1078-0432.CCR-06-2254","article-title":"Targeting von Hippel-Lindau pathway in renal cell carcinoma","volume":"12","author":"Patel","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ijc.10303","article-title":"Loss of tumor suppressor protein PTEN during renal carcinogenesis","volume":"99","author":"Brenner","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib27","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/modpathol.3880551","article-title":"Intragenic PTEN\/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis","volume":"15","author":"Velickovic","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib28","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1097\/01.ju.0000154351.37249.f0","article-title":"Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma","volume":"173","author":"Kim","year":"2005","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.juro.2006.08.076","article-title":"Activation of the mTOR signaling pathway in renal clear cell carcinoma","volume":"177","author":"Robb","year":"2007","journal-title":"J Urol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib30","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/cncr.22677","article-title":"Prognostic relevance of the mTOR pathway in renal cell carcinoma","volume":"109","author":"Pantuck","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3816\/CGC.2007.n.020","article-title":"Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma","volume":"5","author":"Cho","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib33","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib34","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib35","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib37","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Temsirolimus plus interferon alfa phase I trial in patients with advanced renal cell carcinoma","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib38","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib39","first-page":"5","article-title":"Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-\u03b1, or the combination of temsirolimus and interferon-\u03b1 [abstract 4-M181]","author":"de Souza","year":"2007","journal-title":"Eur J Cancer Suppl"},{"issue":"suppl 18S","key":"10.1053\/j.seminoncol.2009.10.013_bib40","first-page":"247s","article-title":"Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-a (IFN) or the combination of IFN + TEMSR [abstract 5049]","volume":"25","author":"Parasuraman","year":"2007","journal-title":"J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I"},{"issue":"suppl 15S","key":"10.1053\/j.seminoncol.2009.10.013_bib41","first-page":"262s","article-title":"Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features [abstract 5050]","volume":"26 part I","author":"Logan","year":"2008","journal-title":"J Clin Oncol, 2008 ASCO Annual Meeting Proceedings"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib42","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","article-title":"Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies","volume":"26","author":"Dutcher","year":"2009","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib43","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1002\/cncr.24409","article-title":"Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma","volume":"115","author":"Kapoor","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib45","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib46","doi-asserted-by":"crossref","first-page":"764s","DOI":"10.1158\/1078-0432.CCR-06-1975","article-title":"Opportunities and obstacles to combination targeted therapy in renal cell cancer","volume":"13","author":"Sosman","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"suppl 18S","key":"10.1053\/j.seminoncol.2009.10.013_bib47","first-page":"141s","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies [abstract 3512]","volume":"25","author":"Patnaik","year":"2007","journal-title":"J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I"},{"key":"10.1053\/j.seminoncol.2009.10.013_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","article-title":"Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma","volume":"7","author":"Patel","year":"2009","journal-title":"Clin Genitourin Cancer"},{"issue":"suppl 18S","key":"10.1053\/j.seminoncol.2009.10.013_bib49","first-page":"243s","article-title":"Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results [abstract 5034]","volume":"25 part I","author":"Merchan","year":"2007","journal-title":"J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I"},{"issue":"suppl 15s","key":"10.1053\/j.seminoncol.2009.10.013_bib50","first-page":"244s","article-title":"Phase I\/II trial of CCI-779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients [abstract 5039]","volume":"27","author":"Merchan","year":"2009","journal-title":"J Clin Oncol, 2009 ASCO Annual Meeting Proceedings"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540900195X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540900195X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:14:46Z","timestamp":1558685686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377540900195X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":45,"alternative-id":["S009377540900195X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2009.10.013","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}